Access Dermatology

Breaking News

• Breaking News List »
• 2010 »
• March »

Efficacy and tolerability of alitretinoin in treating severe chronic hand eczema

Three trials were conducted to evaluate the efficacy and safety of oral alitretinoin (10 or 30 mg/day) in the treatment of severe chronic hand eczema (CHE). Trial A was a double-blind, randomized, placebo-controlled study in 1,032 patients using 10 or 30 mg/day alitretinoin or placebo for 24 weeks. Trial B was an open-label, fixed dose (alitretinoin 30 mg/day) in 249 patients for 24 weeks. Trial C was a double-blind, placebo-controlled study of 117 patients who responded in study A and relapsed within 24 weeks. Patients were rerandomized to a second dose of alitretinoin or placebo. In trial A, a "clear" or "almost clear" response on the Physician's Global Assessment was significantly greater ...